Camostat mesylate in COVID-19 Outpatients
Diseases of the Respiratory Systems | COVID-19 Outpatient
What is the purpose of this trial?
The rationale of the present clinical trial is that an orally available drug given to outpatients that could reduce the viral burden in the upper respiratory tract could forestall complications of SARS-CoV-2 infection and reduce transmission from one infected individual to another.
- Ages18 years and older
- Trial withOno Pharmaceutical Co., Ltd.
- Start Date06/16/2020
- End Date05/30/2021
- Last Updated09/11/2020
- Study HIC#2000027971